The Experts below are selected from a list of 9648 Experts worldwide ranked by ideXlab platform
M Charles M D Epstein - One of the best experts on this subject based on the ideXlab platform.
-
accelerated repetitive transcranial magnetic stimulation for Treatment Resistant Depression
Depression and Anxiety, 2010Co-Authors: E Paul M D Holtzheimer, M William M D Mcdonald, M Mustafa D Mufti, Mary E Kelley, B Sinead A Quinn, M German D Corso, M Charles M D EpsteinAbstract:Background Repetitive transcranial magnetic stimulation (rTMS) has shown safety and efficacy for Treatment-Resistant Depression (TRD) but requires daily Treatment over 4–6 weeks. Accelerated TMS, with all Treatments delivered over a few days, would have significant advantages in terms of access and patient acceptance.
J B Stroud - One of the best experts on this subject based on the ideXlab platform.
-
psilocybin with psychological support improves emotional face recognition in Treatment Resistant Depression
Psychopharmacology, 2018Co-Authors: J B Stroud, David J. Nutt, Robert Leech, Tom P Freeman, Chandni Hindocha, Will Lawn, H V Curran, Robin L CarhartharrisAbstract:RATIONALE: Depressed patients robustly exhibit affective biases in emotional processing which are altered by SSRIs and predict clinical outcome. OBJECTIVES: The objective of this study is to investigate whether psilocybin, recently shown to rapidly improve mood in Treatment-Resistant Depression (TRD), alters patients' emotional processing biases. METHODS: Seventeen patients with Treatment-Resistant Depression completed a dynamic emotional face recognition task at baseline and 1 month later after two doses of psilocybin with psychological support. Sixteen controls completed the emotional recognition task over the same time frame but did not receive psilocybin. RESULTS: We found evidence for a group × time interaction on speed of emotion recognition (p = .035). At baseline, patients were slower at recognising facial emotions compared with controls (p < .001). After psilocybin, this difference was remediated (p = .208). Emotion recognition was faster at follow-up compared with baseline in patients (p = .004, d = .876) but not controls (p = .263, d = .302). In patients, this change was significantly correlated with a reduction in anhedonia over the same time period (r = .640, p = .010). CONCLUSIONS: Psilocybin with psychological support appears to improve processing of emotional faces in Treatment-Resistant Depression, and this correlates with reduced anhedonia. Placebo-controlled studies are warranted to follow up these preliminary findings.
-
Psilocybin with psychological support improves emotional face recognition in Treatment-Resistant Depression
Psychopharmacology, 2018Co-Authors: J B Stroud, David J. Nutt, Robert Leech, Tom P Freeman, Chandni Hindocha, Will Lawn, H V Curran, R. L. Carhart-harrisAbstract:Rationale Depressed patients robustly exhibit affective biases in emotional processing which are altered by SSRIs and predict clinical outcome. Objectives The objective of this study is to investigate whether psilocybin, recently shown to rapidly improve mood in Treatment-Resistant Depression (TRD), alters patients’ emotional processing biases. Methods Seventeen patients with Treatment-Resistant Depression completed a dynamic emotional face recognition task at baseline and 1 month later after two doses of psilocybin with psychological support. Sixteen controls completed the emotional recognition task over the same time frame but did not receive psilocybin. Results We found evidence for a group × time interaction on speed of emotion recognition ( p = .035). At baseline, patients were slower at recognising facial emotions compared with controls ( p
Suravi Patra - One of the best experts on this subject based on the ideXlab platform.
-
Return of the psychedelics: Psilocybin for Treatment Resistant Depression
Asian Journal of Psychiatry, 2016Co-Authors: Suravi PatraAbstract:Psilocybin, the clinically most researched classic psychedelic has recently been tested for its safety and efficacy in a clinical population of Treatment Resistant Depression. The efficacy of psilocybin in clinical Depression previously demonstrated in the elecrophysiologic and neuroimaging findings as also in neuropsychological assessments is further validated by the findings of this rigorously conducted randomized trial. Mechanism of action of psilocybin and efficacy in Treatment Resistant Depression are discussed in this paper. Ethical issues of conducting clinical trials with psychedelics are also discussed with particular emphasis on their relative safety and absence of addiction potential. Implications of these issues for conduct of larger trials for establishing risk benefit ratio in Treatment Resistant Depression are further suggested.
Charles B Nemeroff - One of the best experts on this subject based on the ideXlab platform.
-
prevalence and management of Treatment Resistant Depression
The Journal of Clinical Psychiatry, 2007Co-Authors: Charles B NemeroffAbstract:Treatment-Resistant Depression (TRD) is a major public health problem in terms of its prevalence and in terms of individual suffering and cost to society. Best estimates indicate 12-month prevalence rates of approximately 3% for Stage 1 TRD (failure to respond to 1 adequate trial of an antidepressant) and approximately 2% for Stage 2 TRD (failure to respond to 2 adequate trials). The current article provides a brief review of the definitions, prevalence, and various Treatment options for TRD, including switching, augmentation, and combination therapies and use of nonpharmacologic Treatments. Given the public health importance of TRD, the relative absence of adequately powered, double-blind trials is striking.
-
VNS Therapy in Treatment-Resistant Depression: Clinical Evidence and Putative Neurobiological Mechanisms
Neuropsychopharmacology, 2006Co-Authors: Charles B Nemeroff, Helen S. Mayberg, Scott E Krahl, James Mcnamara, Alan Frazer, Thomas R Henry, Mark S George, Dennis S Charney, Stephen K BrannanAbstract:Currently available therapeutic interventions for Treatment-Resistant Depression, including switch, combination, and augmentation strategies, are less than ideal. Observations of mood elevation during vagus nerve stimulation (VNS) therapy for pharmacoResistant epilepsy suggested a role for VNS therapy in refractory major Depression and prompted clinical investigation of this neurostimulation modality. The VNS Therapy System™ has been available for Treatment of pharmacoResistant epilepsy since 1997 and was approved by the US Food and Drug Administration for Treatment-Resistant Depression in July, 2005. The physiology of the vagus nerve, mechanics of the VNS Therapy System™, and efficacy and safety in pharmacoResistant epilepsy are reviewed. Promising results of VNS therapy for Treatment-Resistant Depression have been forthcoming from both acute and long-term studies, evidenced in part by progressive improvements in Depression rating scale scores during the 1st year of Treatment with maintenance of response thereafter. VNS therapy is well tolerated in patients with either pharmacoResistant epilepsy or Treatment-Resistant Depression. As in epilepsy, the mechanisms of VNS therapy of Treatment-Resistant Depression are incompletely understood. However, evidence from neuroimaging and other studies suggests that VNS therapy acts via innervation of the nucleus tractus solitarius, with secondary projections to limbic and cortical structures that are involved in mood regulation, including brainstem regions that contain serotonergic (raphe nucleus) and noradrenergic (locus ceruleus) perikarya that project to the forebrain. Mechanisms that mediate the beneficial effects of VNS therapy for Treatment-Resistant Depression remain obscure. Suggestions for future research directions are described.
-
VNS therapy in Treatment-Resistant Depression: clinical evidence and putative neurobiological mechanisms.
Neuropsychopharmacology, 2006Co-Authors: Charles B Nemeroff, Helen S. Mayberg, Scott E Krahl, Alan Frazer, Thomas R Henry, Mark S George, Dennis S Charney, James O Mcnamara, Stephen K BrannanAbstract:VNS Therapy in Treatment-Resistant Depression: Clinical Evidence and Putative Neurobiological Mechanisms
Robin L Carhartharris - One of the best experts on this subject based on the ideXlab platform.
-
psilocybin with psychological support improves emotional face recognition in Treatment Resistant Depression
Psychopharmacology, 2018Co-Authors: J B Stroud, David J. Nutt, Robert Leech, Tom P Freeman, Chandni Hindocha, Will Lawn, H V Curran, Robin L CarhartharrisAbstract:RATIONALE: Depressed patients robustly exhibit affective biases in emotional processing which are altered by SSRIs and predict clinical outcome. OBJECTIVES: The objective of this study is to investigate whether psilocybin, recently shown to rapidly improve mood in Treatment-Resistant Depression (TRD), alters patients' emotional processing biases. METHODS: Seventeen patients with Treatment-Resistant Depression completed a dynamic emotional face recognition task at baseline and 1 month later after two doses of psilocybin with psychological support. Sixteen controls completed the emotional recognition task over the same time frame but did not receive psilocybin. RESULTS: We found evidence for a group × time interaction on speed of emotion recognition (p = .035). At baseline, patients were slower at recognising facial emotions compared with controls (p < .001). After psilocybin, this difference was remediated (p = .208). Emotion recognition was faster at follow-up compared with baseline in patients (p = .004, d = .876) but not controls (p = .263, d = .302). In patients, this change was significantly correlated with a reduction in anhedonia over the same time period (r = .640, p = .010). CONCLUSIONS: Psilocybin with psychological support appears to improve processing of emotional faces in Treatment-Resistant Depression, and this correlates with reduced anhedonia. Placebo-controlled studies are warranted to follow up these preliminary findings.
